Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The study met its primary endpoint with flying colors
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Subscribe To Our Newsletter & Stay Updated
